BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35852645)

  • 21. XPG polymorphisms and their association with lung cancer susceptibility, overall survival and response in North Indian patients treated with platinum-based doublet chemotherapy.
    Lawania S; Singh N; Behera D; Sharma S
    Future Oncol; 2019 Jan; 15(2):151-165. PubMed ID: 30522358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumors.
    Sun XH; Hou WG; Zhao HX; Zhao YL; Ma C; Liu Y
    Asian Pac J Cancer Prev; 2013; 14(3):2049-52. PubMed ID: 23679317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
    Isla D; Sarries C; Rosell R; Alonso G; Domine M; Taron M; Lopez-Vivanco G; Camps C; Botia M; Nuñez L; Sanchez-Ronco M; Sanchez JJ; Lopez-Brea M; Barneto I; Paredes A; Medina B; Artal A; Lianes P
    Ann Oncol; 2004 Aug; 15(8):1194-203. PubMed ID: 15277258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer.
    Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Robles AI; Faus-Dáder MJ; Calleja-Hernández MÁ
    Mutat Res Rev Mutat Res; 2017; 771():32-58. PubMed ID: 28342452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy.
    Zou HZ; Zhao YQ
    Genet Mol Res; 2015 Jan; 14(1):500-6. PubMed ID: 25729984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese.
    Xu JL; Hu LM; Huang MD; Zhao W; Yin YM; Hu ZB; Ma HX; Shen HB; Shu YQ
    Asian Pac J Cancer Prev; 2012; 13(3):851-6. PubMed ID: 22631660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer.
    Cheng J; Ha M; Wang Y; Sun J; Chen J; Wang Y; Tong C
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):231-8. PubMed ID: 22102173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.
    Hamilton G; Rath B
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):17-24. PubMed ID: 29226731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.
    Wang YD; Ha MW; Cheng J; Zhang WL; Cong X; Tong CY; Sun J
    Oncol Rep; 2012 Apr; 27(4):979-86. PubMed ID: 22179630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Chen X; Sun H; Ren S; Kim Curran V; Zhang L; Zhou S; Zhang J; Zhou C
    Clin Transl Oncol; 2012 Mar; 14(3):207-13. PubMed ID: 22374424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
    Zhu XL; Sun XC; Chen BA; Sun N; Cheng HY; Li F; Zhang HM; Feng JF; Qin SK; Cheng L; Lu ZH
    Chin Med J (Engl); 2010 Dec; 123(23):3427-32. PubMed ID: 22166526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RB1 polymorphism contributes to the efficacy of platinum-taxanes in advanced squamous cell lung cancer.
    Liu D; Xu W; Zhang ZW; Qian J; Zheng H; Zhang J; Su B
    Asian Pac J Cancer Prev; 2015; 16(2):775-81. PubMed ID: 25684524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy.
    Chen J; Luo X; Xie G; Chen K; Jiang H; Pan F; Li J; Ruan Z; Pang X; Liang H
    Medicine (Baltimore); 2016 May; 95(19):e3652. PubMed ID: 27175691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between ERCC5 gene polymorphisms and gastric cancer risk in a Chinese population.
    Li RJ; Li M; Liu GJ; Guo YW; Bai H; Xiao P; Mei JZ
    Genet Mol Res; 2016 Mar; 15(1):. PubMed ID: 27051028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Promoter polymorphisms in DNA repair gene ERCC5 and susceptibility to gastric cancer in Chinese.
    Duan Z; He C; Gong Y; Li P; Xu Q; Sun LP; Wang Z; Xing C; Yuan Y
    Gene; 2012 Dec; 511(2):274-9. PubMed ID: 22982416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variations within 3'-UTR of MDM4 gene contribute to clinical outcomes of advanced non-small cell lung cancer patients following platinum-based chemotherapy.
    Yang Y; Gao W; Ding X; Xu W; Liu D; Su B; Sun Y
    Oncotarget; 2017 Mar; 8(10):16313-16324. PubMed ID: 27462918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.